Actively Recruiting
Observing Diagnosis and Treatment Practices for Stage II-IVB Gastric and Gastroesophageal Junction Cancer Patients in Greece A Multicenter Observational Study Sponsored by AstraZeneca
Led by AstraZeneca · Updated on 2026-10-08
300
Participants Needed
8
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a retrospective-prospective observational study in Greece to understand how patients with stage II to IVB gastric or gastroesophageal junction GEJ adenocarcinoma are diagnosed and treated in real-world medical settings. The study aims to describe the epidemiological features and management approaches among these patients across multiple oncology clinics in both public and private hospitals. The study includes adult patients diagnosed between June 1, 2025, and the end of recruitment in 2027. It collects data retrospectively and prospectively without administering any experimental treatments. The focus is on capturing treatment patterns, timing, and dosing strategies used in routine clinical care for this cancer type. Participants will provide information during their first visit and be observed for up to 18 months to track treatment strategies and key time intervals between diagnosis, surgery, and systemic therapies. Researchers will also collect clinicopathological characteristics, biomarker testing data, and treatment durations. Patients can withdraw anytime, and efforts will be made to document outcomes if possible.
CONDITIONS
Brief Title
A Study in Greece Observing How Patients With Stomach and Esophageal Cancer Are Diagnosed and Treated in Everyday Medical Practice
Research Team
A
AstraZeneca Clinical Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here